Abstract
Glioblastoma (GBM) is an aggressive tumor that affects adult individuals. Because of this, the patient's median survival is estimated at just 15 months. Standard treatment consists of surgical resection followed by radiotherapy and chemotherapy with temozolomide (TMZ). Despite this, the tumor is highly recurrent. This pattern can be explained by the resistance GBM stem cells (GSC) acquire…